Date:2/17/2011

charged to selling, general and administrative, in the respective periods.(e) A net recovery in the amount of $0.3 million during the fourth quarter of 2010, relating to inventory write-ups recorded in connection with acquisitions. (See also footnote k below.)(f) A write-off in the amount of $1.4 million during the fourth quarter of 2009, relating to inventory write-ups recorded in connection with acquisitions.  (g) A goodwill impairment charge during the fourth quarter of 2010 in the amount of $1.0 billion related to our health management reporting unit and business segment.(h) A $60.1 million compensation charge associated with our acquisition of minority shares of Standard Diagnostics, Inc. during the fourth quarter of 2010.(i) Acquisition-related costs in the amount of $1.4 million and $4.3 million in the fourth quarter of 2010 and 2009 GAAP results, respectively, recorded in connection with ASC 805, Business Combinations. (j) $4.1 million and $1.8 million of expense in the fourth quarter of 2010 and 2009 GAAP results, respectively, recorded in connection with fair value adjustments to acquisition-related contingent consideration obligations in accordance with ASC 805, Business Combinations.(k) Amortization expense of $0.3 million ($0.3 million, net of tax) attributable to operating results of non-controlling interests.(l) A $0.7 million and $3.2 million fair value write-down in the fourth quarter of 2010 and 2009, respectively, recorded in connection with an idle facility.(m) Expenses of $18.0 thousand ($11.0 thousand, net of tax) and $1.8 million ($1.1 million, net of tax) in the fourth quarter of 2010 and 2009, respectively, incurred in connection with the sale of our vitamins and nutritional supplements business.(n) Tax effect on adjustments as discussed above in notes (b), (c), (d), (e), (f) (g), (h), (i), (j) and (l).(o) For the three months ended December 31, 2010 and 2009, potential dilutive shares were not used in the calculation of diluted net los
'/>"/>

SOURCE Alere Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related medicine technology :

1. Inverness Medical Innovations Changes Name to Alere
2. Alere Inc. Schedules Conference Call for 10:00 a.m. ET July 28, 2010 to Discuss Second Quarter 2010 Results
3. Alere and AirStrip Technologies - a Powerful Collaboration Brings Innovative Remote Patient Monitoring to Obstetrical Care
4. Alere Inc. Announces Offering of $350 Million of Senior Subordinated Notes
5. Alere Inc. Announces Pricing of Senior Subordinated Notes Offering; Offering Size Increased to $400.0 Million
6. Alere to Attend the Fifth Annual JMP Securities Healthcare Conference on September 28, 2010
7. Alere to Attend the Lazard Capital Markets 7th Annual Healthcare Conference on November 17, 2010
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer